Phase II/III CRO Benchmarking (18th Ed.)

ISR’s CRO Benchmarking reports are our longest-standing studies and we take pride in the role our research has played in the growth of the clinical development landscape over the years.

This year, ISR surveyed 209 experienced Phase II/III outsourcers and collected their insights on 829 recent service provider encounters with Phase II/III CROs. These data on selection drivers, provider perception in the marketplace, provider performance, and customer satisfaction will help CROs optimize marketing and operational strategies.

What you will learn:

Service Provider Selection Process

• Use of preferred provider agreements across company sizes
• Key CRO selection drivers across three decision-making scenarios
• Use of outside consultants for CRO identification and selection

Service Provider Perceptions and Interactions

• Leadership, familiarity, and reported recent use of Phase II/III CROs
• Service provider preference (overall and among users of each provider)

Service Provider Performance and Loyalty

• Recent customers provide performance ratings on 21 attributes across delivery factors, staff characteristics, services, and project delivery across geographies
• Customer loyalty (2026 ratings and 3-year rolling average)

Service Provider Cost and Value

• Cost perceptions (overall and among users of each provider)
• Customer satisfaction with value received
• CRO performance on appropriateness of change orders

Company Service Quality Profiles

• Summaries of Phase II/III CRO brand metrics and performance metrics
• Verbatim customer rationale for provider satisfaction ratings

Included Providers:

Companies listed in bold print have been reviewed by 10 or more respondents. These providers are included in an in-depth performance analysis.

• Advanced Clinical
• Allucent
• Altasciences
• Caidya
• ClinChoice
• CTI Clinical Trial & Consulting
• DCRI-Duke
• Emerald Clinical Trials (formerly George Clinical)
• Emmes CRO
• Eurofins
• Fortrea
• ICON
• Indero (formerly Innovaderm)
• IQVIA
• Lambda
• Medpace
• Novotech
• Novum
• Ora
• Parexel
• PPD (part of Thermo Fisher)
• Precision for Medicine
• Premier Research
• ProPharma
• ProSciento
• PSI
• QPS
• SGS Health Science
• Syneos Health
• UBC
• Veristat
• Worldwide Clinical Trials
• WuXi Clinical

Respondents were required to pass several screening criteria to qualify and participate in this survey:

• Must work at a pharmaceutical company, biotech company, or medical device company
• Must have responsibility in at least one of several relevant areas such as Clinical Operations, Project Management, Executive Management, Medical, Outsourcing/Procurement, or Research and Development Management
• Must have involvement with outsourced Phase II/III trials within past 12 months